NCMAG122 Pembrolizumab advice document: April 2025
Posted on:
Document Type
NCMAG advice
Process guidance
Summary
Pembrolizumab for the neoadjuvant treatment of stage IIIB to IIID or oligometastatic resectable stage IV melanoma. Off-label use.
Decision: Supported